Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.14.01 | Diabetes and obesity – Clinical diabetes | ECE2015

What components drive the metabolic syndrome? Results from the population-based LifeLines Cohort Study

Slagter Sandra N , Waateringe Robert P van , Wendker Marjolein , Vliet-Ostaptchouk Jana V van , Lutgers Helen L , Beek Andre P van , Klauw Melanie M van der , Wolffenbuttel Bruce H R

Background: The metabolic syndrome (MetS) is a combination of unfavourable health factors including visceral obesity, dyslipidaemia, hypertension and impaired fasting glucose. It is also strongly associated with increased risk of cardiovascular disease (CVD) and type 2 diabetes. We assessed which factors contribute to the prevalence of MetS in people within different weight and age categories.Methods: 64 046 western European participants aged 18–80 ...

ea0029p538 | Diabetes | ICEECE2012

The burden of disease in elderly people with IFG

Lutgers H. , Campbell L. , Baune B. , Brodaty H. , Trollor J. , Sachdev P. , Samaras K.

Introduction: The prevalence of impaired fasting glucose (IFG) in the elderly approaches 50% in some community-dwelling cohorts. We examined whether IFG is associated with a higher burden of disease, cardiovascular risk factors and circulating low-grade inflammation than in normoglycemic elderly people.Methods/Design: Cross-sectional data of 929 participants of the Sydney Memory and Aging Study (MAS) were examined. MAS is a population-derived cohort of c...

ea0035p761 | Obesity | ECE2014

Health-related quality of life relates to obesity and low-grade inflammation in obese individuals

Slagter Sandra , Wolffenbuttel Bruce , Beek Andre Van , Lutgers Helen , Vliet-Ostaptchouk Jana Van , Klauw Melanie Van der

Introduction: Obesity is increasingly prevalent in Western society. In addition to medical consequences, obesity also affects health-related quality of life (HR-QOL).Design: We assessed the differences in HR-QOL in obese participants with and without metabolic syndrome (MetS), by level of obesity and level of inflammation, in the LifeLines Cohort study, a population-based study. In total, 12 765 subjects age 18–80 years, with BMI >30 kg/m2<...

ea0035p760 | Obesity | ECE2014

Worsening of cardiovascular risk with increasing number of components of metabolic syndrome in obese non-diabetic individuals

Wolffenbuttel Bruce , Slagter Sandra , Beek Andre Van , Lutgers Helen , Vliet-Ostaptchouk Jana Van , Klauw Melanie Van der

Introduction: The metabolic syndrome (MetS) is a strong predictor of cardiovascular risk. It is influenced by environmental factors, and its prevalence is high in subjects with obesity.Design: We assessed differences in glucose- and lipid parameters, and hsCRP and microalbuminuria (MA) in obese subjects with and without metabolic syndrome (MetS) in LifeLines, a population-based study. Included were subjects 18–80 years, with BMI>30 kg/m2</s...

ea0011p830 | Thyroid | ECE2006

Increase of L-thyroxine requirement during pregnancy

Russo L , Tonacchera M , Gianetti E , Perri A , Vitti P , Pinchera A

In pregnant women with thyroid diseases an increased amount of LT4 may be required for the correction of hypothyroidism or treatment of nodular goiter. Aim of this study was to assess the amount of the variations of LT4 requirement in pregnant women with thyroid diseases. To address this issue, we retrospectively evaluated a cohort of 107 women treated with LT4 divided in two groups: 42 euthyroid (E) (affected by nodular goiter (NG) treated with LT4 suppressive therapy) and 65...

ea0041ep779 | Obesity | ECE2016

Skin autofluorescence is associated with the metabolic syndrome and its individual components

van Waateringe Robert , Slagter Sandra , van Vliet-Ostaptchouck Jana , Graaff Reindert , van der Klauw Melanie , Paterson Andrew , Lutgers Helen , Wolffenbuttel Bruce

Background: Skin autofluorescence (SAF) has been demonstrated to be associated with long-term cardiovascular complications in subjects with either diabetes or renal failure. Since the metabolic syndrome (MetS) is a risk factor for cardiovascular disease, the aim of the study was to assess the association between SAF and MetS as well as its individuals components.Materials and methods: For this cross-sectional analysis, we included subjects 18–80 yea...

ea0029oc3.6 | Diabetes Clinical | ICEECE2012

Glucose disorders exert a detrimental effect on total brain volume in the elderly: a 2-year prospective MRI study

Samaras K. , Lutgers H. , Wen W. , Campbell L. , Baune B. , Brodaty H. , Trollor J. , Sachdev P.

Introduction: Long-standing type 2 diabetes (DM) is associated with brain atrophy. In this prospective study we examined the impact of glycaemic status on total brain volume in an elderly cohort.Methods/Design: Two-year follow-up study of a population-derived cohort of non-demented community-dwelling adults aged 70–90 years (Sydney Memory and Aging Study). Prospective MRI and metabolic data were available in 312 of the 542 participants who had a MRI...

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...

ea0074oc1 | Oral Communications | SFENCC2021

A rare heterozygous IGFI variant causing postnatal growth failure and offering novel insights into IGF-I physiology

Cottrell Emily , Chatterjee Sumana , Hwa Vivian , Storr Helen L.

Section 1: Case history: A 10-year-old girl presented with significant postnatal growth failure. Her birth weight was normal (–0.15SDS) but poor growth was observed from a few months of age. She had no other symptoms. On examination, height was –3.4SDS and head circumference –1.6SDS. She had no dysmorphic features and normal development. Section 2: Investigations: Baseline serum analyses were unremarkable. Karyotype was normal (46XX). Bone age was delayed by 2.5...

ea0009p55 | Growth and development | BES2005

Constitutional delay of growth and puberty (CDGP)is associated with the GPR54 gene but not with Leptin (L), Leptin Receptor (LR) and Cocaine and Amphetamin Regulated Transcript (CART) genes

Banerjee I , Trueman J , Patel L , Hall C , Price D , Hirschhorn J , Palmert M , Read A , Clayton P

CDGP is a common growth disorder, often dominantly inherited. Genetic association is thus very likely. There are many possible candidates but none are yet linked to CDGP. We assessed the possible contribution of L, LR genes (mutations in each cause very delayed or absent puberty), CART (mediates the effect of L on GnRH pulse generation), and GPR54 (a hypothalamic G-protein coupled receptor, which is mutated in familial hypogonadotrophic hypogonadism) genes.<p class="abstex...